文献速递结核与非结核分枝杆菌

贝达喹啉与德拉马尼单用或联用对耐利福平结核患者QT间期的影响:2期开放标签随机对照试验

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Infect Dis · 2021-02-12

ACTG A5343为2期开放标签随机对照试验,纳入84例耐多药或耐利福平结核成人,随机接受贝达喹啉、德拉马尼或两者联合24周。

要点

  • 未发生3/4级QT延长不良事件及治疗期间死亡。
  • 24周培养转阴率联合组95%,单药组91%–92%。

核心结论

  • 贝达喹啉与德拉马尼联合对QTc间期有轻度、不超过相加效应的影响,初始微生物学数据令人鼓舞,支持在基线QTc正常的耐多药或耐利福平结核患者中联用。

研究设计与样本

  • ACTG A5343为2期、开放标签、随机对照试验,在南非两家中心和秘鲁一家中心开展。
  • 174例筛选,84例耐多药或耐利福平结核成人按1:1:1随机接受贝达喹啉、德拉马尼或两者联合24周,每组28例,HIV阳性共31例。
  • 主要终点为第8–24周平均QTcF较基线变化,探索性终点为第8–24周累积培养转阴,分析采用改良意向性治疗人群。

主要发现

  • 研究治疗期间无3级或4级QTc延长不良事件,无死亡。
  • 第8周累积培养转阴:贝达喹啉21/24(88%,95%CI 71–97),德拉马尼20/24(83%,65–95),联合组19/20(95%,79–100)。
  • 第24周培养转阴:贝达喹啉92%(77–99),德拉马尼91%(76–99),联合组95%(79–100)。

关键数值与推荐

  • 入组排除QTc大于450 ms者,HIV阳性者接受基于多替拉韦的抗逆转录病毒治疗。
  • 禁用氯法齐明,以左氧氟沙星替代莫西沙星。
  • 每两周进行三份心电图和痰培养。

临床怎么用

  • 对基线QTc正常的耐多药或耐利福平结核患者,可考虑贝达喹啉与德拉马尼联用,但需纵向监测QTc。
  • 联合用药的QTc延长幅度在可接受范围,未出现严重QT延长事件。

局限性

  • 样本量较小,每组28例,联合组培养转阴分析仅20例。
  • 为开放标签设计,未设安慰剂对照。
  • 随访限于24周治疗期内,未报告长期心脏安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bedaquiline and delamanid are the first drugs of new classes registered for tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects occurring weeks after drug initiation. The cardiac safety and microbiological activity of these drugs when co-administered are not well-established. Our aim was to characterise the effects of bedaquiline, delamanid, or both on the QTc interval, longitudinally over 6 months of multidrug treatment, among patients with multidrug-resistant or rifampicin-resistant tuberculosis taking multidrug background therapy. METHODS: ACTG A5343 is a phase 2, open-label, randomised, controlled trial in which adults with multidrug-resistant or rifampicin-resistant tuberculosis receiving multidrug background treatment were randomly assigned 1:1:1 by centrally, computer-generated randomisation, by means of permuted blocks to receive bedaquiline, delamanid, or both for 24 weeks. Participants were enrolled at TASK in Cape Town and the South African Tuberculosis Vaccine Initiative in Worcester, both in South Africa, and Hospital Maria Auxiliadora in Peru. Individuals with QTc greater than 450 ms were excluded. HIV-positive participants received dolutegravir-based antiretroviral therapy. Clofazimine was disallowed, and levofloxacin replaced moxifloxacin. ECG in triplicate and sputum cultures were done fortnightly. The primary endpoint was mean QTcF change from baseline (averaged over weeks 8-24); cumulative culture conversation at week 8-24 was an exploratory endpoint. Analyses included all participants who initiated study tuberculosis treatment (modified intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT02583048 and is ongoing. FINDINGS: Between Aug 26, 2016 and July 13, 2018, of 174 screened, 84 participants (28 in each treatment group, and 31 in total with HIV) were enrolled. Two participants did not initiate study treatment (one in the delamanid group withdrew consent and one in the bedaquiline plus delamanid group) did not meet the eligibility criterion). Mean change in QTc from baseline was 12·3 ms (95% CI 7·8-16·7; bedaquiline), 8·6 ms (4·0-13·1; delamanid), and 20·7 ms (16·1-25·3) (bedaquiline plus delamanid). There were no grade 3 or 4 adverse QTc prolongation events and no deaths during study treatment. Cumulative culture conversion by week 8 was 21 (88%) of 24 (95% CI 71-97; bedaquiline), 20 (83%) of 24 (65-95; delamanid), and 19 (95%) of 20 (79-100; bedaquiline plus delamanid) and was 92% (77-99) for bedaquiline, 91% (76-99), for delamanid, and 95% (79-100) for bedaquiline plus delamanid at 24 weeks. INTERPRETATION: Combining bedaquiline and delamanid has a modest, no more than additive, effect on the QTc interval, and initial microbiology data are encouraging. This study provides supportive evidence for use of these agents together in patients with multidrug-resistant or rifampicin-resistant tuberculosis with normal baseline QTc values. FUNDING: Division of AIDS, National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021. PMID: 33587897. doi:10.1016/S1473-3099(20)30770-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。